PT - JOURNAL ARTICLE AU - Qing Lei AU - Yang Li AU - Hongyan Hou AU - Feng Wang AU - Yandi Zhang AU - Danyun Lai AU - Banga Ndzouboukou Jo-Lewis AU - Zhaowei Xu AU - Bo Zhang AU - Hong Chen AU - Zhuqing Ouyang AU - Junbiao Xue AU - Xiaosong Lin AU - Yunxiao Zheng AU - Zhongjie Yao AU - Xuening Wang AU - Caizheng Yu AU - Hewei Jiang AU - Hainan Zhang AU - Huan Qi AU - Shujuan Guo AU - Shenghai Huang AU - Ziyong Sun AU - Shengce Tao AU - Xionglin Fan TI - Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients AID - 10.1101/2020.07.09.20149633 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.09.20149633 4099 - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149633.short 4100 - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149633.full AB - Humoral immunity in asymptomatic infections with SARS-CoV-2 has not been well established. 63 healthy contacts, 63 asymptomatic individuals, and 51 mild patients were enrolled in this study and screened using nucleic acid testing (NAT) and commercial kits of serum IgM and IgG antibodies against recombinant nucleoprotein (N) and spike (S) proteins of SARS-CoV-2. Asymptomatic and mild patients were classified into at least four types based on NAT and serological tests, especially 81% and 25.4% negative NAT but positive IgM/IgG responses, respectively. Antibody dynamics were further demonstrated by IgM and IgG profile responses to SARS-CoV-2 proteome. IgM antibody responses against S1 were elicited in asymptomatic individuals as early to the seventh day after exposure and peaked on days from 17d to 25d, which might be used as early diagnostic biomarkers. Moreover, asymptomatic individuals evoked weaker S1 specific IgM and neutralizing antibody responses than mild patients. Most importantly, S1 specific IgM/IgG responses and the titers of neutralizing antibody in asymptomatic individuals gradually vanished in two months. Our findings might have important implications for serological survey, public health and immunization strategy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the National Mega-Projects of Science Research for the 13th Five-year Plan of China (No. 2018ZX10302302002-001), the Natural Science Foundation of China (No. 81971909), and the Fundamental Research Funds for the Central Universities (HUST COVID-19 Rapid Response Call No. 2020kfyXGYJ040). We declare that no external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (IRB ID:TJ-C20200128). Written informed consent was obtained from all participants enrolled in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.